Sialic acid is a diverse group of monosaccharides often found on the termini of N- and O-linked glycans as well as being components of glycoconjugates. Hypersialylation has been associated with the progression of chronic inflammation-mediated diseases such as cardiovascular disease and cancer. Given its role in infection and disease-related processes, sialic acid is a promising target for therapeutic approaches that utilize carbohydrate-binding molecules. In this study, we screened for sialic acid-recognizing variable lymphocyte receptors (VLRBs) or ccombodies from inshore hagfish (Eptatretus burgeri) using a synthetic Neu5Ac-glycoconjugate as an antigen in immunoassay. Resulting ccombodies, 2D8, 5G11, 4A1, and 5F8 were further characterized in terms of their binding activity and specificity. A competitive ELISA using free haptens showed strong inhibition using either N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc). The half-maximal inhibitory concentrations (IC50) for Neu5Ac ranged from 7.02 to 17.06 mM, with candidates 4A1 and 5G11 requiring the least and highest amounts, respectively. IC50 values for Neu5Gc ranged from 8.12 to 13.91 mM, for 4A1 and 5G11, respectively. Candidate ccombodies also detected naturally occurring sialic acid from known sialoglycoproteins using a dot blot assay. Neu5Gc-5G11 and Neu5Ac-2D8 yielded the strongest and weakest docking interactions with affinity values of −5.9 kcal/mol and −4.9 kcal/mol, respectively. Hydrogen bonding and hydrophobic interactions were predicted to be the predominant noncovalent forces observed between the ccombodies and sialic acid. This study demonstrates that glycan-binding VLRBs from hagfish hold promise in augmenting the glycobiologists’ toolkit in investigating the roles of glycans in human and animal health and disease.
Sialyl-Tn (sTn) is a tumor-associated carbohydrate antigen (TACA) abundantly expressed by various types of carcinomas. While conventional antibody-based platforms have traditionally been used for the detection and targeting of sTn, alternative binding scaffolds may offer distinct advantages. Variable lymphocyte receptor B (VLRB), the immunoglobulin-like molecule of jawless vertebrates, offers a promising alternative for glycan recognition. In this study, a phage-displayed VLRB library was utilized to identify sTn-specific binders. Two candidates, designated as ccombodies A8 and B11, were isolated after four rounds of biopanning. Both were expressed and purified using Ni-affinity and FPLC, yielding proteins with apparent molecular weights of ~27 kDa in SDS-PAGE. Sequence analysis revealed a preference for glycan-binding residues in randomized hypervariable regions, with A8 exhibiting an increased aliphatic content. ELISA confirmed selective binding to sTn and other O-glycans containing the core α-GalNAc, with EC50 values of 18.2 and 14.2 nM for A8 and B11, respectively. Vicia villosa lectin inhibited ccombody binding to sTn, indicating shared epitope recognition. Additionally, both ccombodies bound to sTn-positive glycoproteins and carcinoma cell lines HeLa and LS174T. These findings demonstrate that phage display of VLRBs enables the identification of high-affinity, glycan-specific binders, offering a compelling alternative to immunoglobulin-based platforms for future diagnostic and therapeutic applications targeting tumor-associated glycans.
Enterotoxigenic Bacteroides fragilis (ETBF) weakens the intestinal epithelial barrier and promotes inflammatory signaling through secretion of B. fragilis toxin (BFT), a metalloprotease associated with chronic intestinal inflammation. By triggering the breakdown of the E-cadherin glycoprotein in cellular junctions, BFT compromises tissue integrity and affects pathways involved in tumor suppression and signal transduction. Despite growing evidence implicating BFT in colorectal carcinogenesis, its role remains ambiguous, in part due to limited availability of suitable tools for its detection and neutralization. Selective binding molecules targeting BFT are, therefore, critical for understanding the role of ETBF in these clinical pathologies. Here, we used phage display screening to develop hagfish VLRB-derived consensus scaffold, termed ccombodies, as alternative non-immunoglobulin molecules targeting BFT. Three candidate binders (B8-1, C2-6, and G8-5) were expressed and purified for characterization. Specificity analyses against a range of bacterial virulence factors confirmed the selective recognition of BFT. Binding affinity was determined by ELISA titration and biolayer interferometry (BLI) yielding apparent K D values in the nanomolar range. The ccombodies detected BFT at low nanogram levels by Western blot and exhibited high specificity and sensitivity in toxin recognition. Furthermore, treatment with ccombody attenuated BFT-induced cytotoxicity in Caco-2 and HT-29 epithelial cells. These findings establish ccombodies as a novel class of BFT-targeting molecules with potential applications in selective toxin detection, passive immunoprophylaxis, and antivirulence intervention.